Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: AxCell, Mount Sinai Partner for Nephropathy Research

NEW YORK, April 30 - AxCell Biosciences said today that it will collaborate with Mount Sinai School of Medicine researcher Irwin Gelman to study HIV-assocated nephropathy.

 

The research seeks to identify new treatments for the disease. It is the second partnership between AxCell and Mount Sinai.

 

Under the agreement, AxCell will provide its expertise in signal transduction analysis to find molecules that inhibit interactions between cellular proteins and HIV proteins. Lead molecules will be tested in cell culture and with transgenic mice.

 

The company has an option to negotiate exclusive, worldwide, royalty-bearing licenses from the medical school for any inventions developed in this collaboration.

 

Incidence of HIV-related nephropathy is on the rise, as patients treated with antiretrovirals live longer.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.